GPRC5D是多发性骨髓瘤免疫治疗的靶点:合理设计的CAR T细胞
靶向BCMA的CAR T细胞治疗多发性骨髓瘤早期结果有前景,但低至阴性BCMA表达细胞相关复发需新靶点。研究用定量免疫荧光确认GPRC5D蛋白在CD138+原代骨髓样本MM细胞表达,分布与BCMA相似但独立;筛选42种CAR构建体,GPRC5D(109) CAR T细胞在体内根除MM并长期生存,包括BCMA抗原逃逸模型。
要点
- GPRC5D蛋白在CD138+原代骨髓MM细胞表达,分布与BCMA相似但独立。
- GPRC5D(109) CAR T细胞对MM细胞系和原代MM有细胞毒性、细胞因子释放和体内活性,与抗BCMA CAR T细胞相当。
- 鼠和食蟹猴交叉反应CAR T细胞未引起脱发或其他GPRC5D介导毒性迹象。
核心结论
- GPRC5D(109) CAR T细胞疗法对晚期MM有治疗潜力,不受既往BCMA靶向治疗影响。
研究设计与样本
- 使用定量免疫荧光检测原代骨髓样本CD138+ MM细胞GPRC5D蛋白表达。
- 从人B细胞衍生噬菌体展示库筛选出7个GPRC5D特异性单链可变片段(scFv)。
- 将scFv纳入多种CAR格式产生42种不同构建体,用基于Nur77的报告系统筛选抗原特异性和抗原非依赖性(持续性)信号。
- 用小鼠骨髓趋向性MM异种移植模型在体内确认Nur77报告筛选结果。
主要发现
- GPRC5D蛋白在CD138+ MM细胞表达,分布与BCMA相似但独立。
- 含GPRC5D靶向scFv克隆109的CAR T细胞根除MM并实现长期生存,包括在BCMA抗原逃逸模型中。
- GPRC5D(109)对GPRC5D特异,对MM细胞系和原代MM产生细胞毒性、细胞因子释放和体内活性,与抗BCMA CAR T细胞相当。
- 鼠和食蟹猴交叉反应CAR T细胞在这些物种中未引起脱发或其他GPRC5D介导毒性迹象。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early clinical results of chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation antigen (BCMA) for multiple myeloma (MM) appear promising, but relapses associated with residual low-to-negative BCMA-expressing MM cells have been reported, necessitating identification of additional targets. The orphan G protein-coupled receptor, class C group 5 member D (GPRC5D), normally expressed only in the hair follicle, was previously identified as expressed by mRNA in marrow aspirates from patients with MM, but confirmation of protein expression remained elusive. Using quantitative immunofluorescence, we determined that GPRC5D protein is expressed on CD138+ MM cells from primary marrow samples with a distribution that was similar to, but independent of, BCMA. Panning a human B cell-derived phage display library identified seven GPRC5D-specific single-chain variable fragments (scFvs). Incorporation of these into multiple CAR formats yielded 42 different constructs, which were screened for antigen-specific and antigen-independent (tonic) signaling using a Nur77-based reporter system. Nur77 reporter screen results were confirmed in vivo using a marrow-tropic MM xenograft in mice. CAR T cells incorporating GPRC5D-targeted scFv clone 109 eradicated MM and enabled long-term survival, including in a BCMA antigen escape model. GPRC5D(109) is specific for GPRC5D and resulted in MM cell line and primary MM cytotoxicity, cytokine release, and in vivo activity comparable to anti-BCMA CAR T cells. Murine and cynomolgus cross-reactive CAR T cells did not cause alopecia or other signs of GPRC5D-mediated toxicity in these species. Thus, GPRC5D(109) CAR T cell therapy shows potential for the treatment of advanced MM irrespective of previous BCMA-targeted therapy.
引用
- Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019. PMID: 30918115. doi:10.1126/scitranslmed.aau7746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。